Hybrid of niosomes and bio synthesized selenium nanoparticles as a novel approach in drug delivery for cancer treatment
The current study intends to investigate a novel drug delivery system (DDS) based on niosomes structure (NISM) and bovine serum albumin (BSA) which was formulated to BSA coated NISM (NISM B) Also, selenium nanoparticles (SeNPs) have been prepared by BSA mediated biosynthesis. Finally, the NISM B was hybridized with SeNPs and was formulated as NISM B@SeNPs for drug delivery applications. Physicochemical properties of all samples were characterized by UV Vis spectroscopy, FT IR, DLS, FESEM, and EDX techniques. The cytotoxicity of all samples against A549 cell line was assessed by cell viability analysis and flow cytometry for apoptotic cells as well as RT PCR for the expression of MDR 1, Bax, and Bcl 2 genes. Besides, in vivo biocompatibility was performed by LD50 assay to evaluate the acute toxicity. The proposed formulation has a regular spherical shape and approximately narrow size distribution with proper zeta potential values; the proposed DDS revealed a good biocompatibility. The compound showed a significant cytotoxic effect against A549 cell line. Although the Bax/Bcl 2 expression ratio was significantly in NISM B@SeNPs treated cancer cells, the expression of MDR 1 was non significantly lower in NISM B@SeNPs treated cancer cells. The obtained results suggest that the proposed DDS presents a promising approach for drug delivery, co delivery and multifunctional biomedicine applications.
Molecular Biology Reports